| News | Market | Portfolio | Messages
SENSEX  26,639.04  146.53
NIFTY  7,978.60  45.70
Go to Moneycontrol Home
Margins to scale up to 20% by FY15-end: Dishman Pharma
The company is now concentrating on high margins and high value business and expects a sizable improvement by the end of
USFDA may extend audit at Sun Pharma's Halol facility
CCI begins Sun-Ranbaxy deal's public scrutiny; seeks notes
Sequent Scientific arm Alvira buys 60% in Turkey's Provet
Halol contributes 35-40% to Sun's US sales: Angel Broking
US drug patent expiries to benefit Indian pharma industry
Stock Advice
Buy Sun Pharma, Mahindra Ugine: Pritesh Mehta
Accumulate Lupin for long term: Phani Sekhar
See no incremental gains for Lupin in FY15-16: Surajit Pal
Broker Reports
Buy Strides Arcolab; target of Rs 900: Religare Capital
Buy Sun Pharma; target of Rs 944: Firstcall Research
Hold Glenmark Pharma; target of Rs 805: Sharekhan
Budget 2012
Font Size: S M L
Mobile | Classic
Customer Support
© 2011. a Web18 Venture